To prevent a clinically relevant cytokine release syndrome (CRS), the anti‐IL‐6R antibody Tocilizumab was applied as soon as a fever of ≥ 38.5° occurred for the first time. This evidence concerns the gene IL6R and congenital rubella syndrome.